Table 1.
Demographics and clinicopathological characteristics of 250 unilateral papillary thyroid carcinoma patients.
| Characteristics | Number (%) |
|---|---|
| No. of patients | 250 (100) |
| Sex | |
| Male/female | 49 (19.6)/201 (80.4) |
| Age (mean ± SD, (range)), years | 39.67 ± 11.36 (18–70) |
| ≥55/<55 | 25 (10.0)/225 (90.0) |
| Primary tumor size (mean ± SD), mm | 15.95 ± 10.25 |
| ≤10/>10 | 95 (38.0)/155 (62.0) |
| Hashimoto's thyroiditis | |
| Yes/No | 120 (48.0)/130 (52.0) |
| BRAF V600E mutation | |
| Positive/negative | 179 (71.6)/71 (28.4) |
| Multifocality | |
| Yes/No | 21 (8.4)/229 (91.6) |
| Capsular invasion | |
| Present/absent | 83 (33.2)/167 (66.8) |
| ETE | |
| Present/absent | 58 (23.2)/192 (76.8) |
| cN0/cN1 | 130 (52.0)/120 (48.0) |
| CLNM | 157 (62.8) |
| Bi-CLNM | 72 (45.9) |
| Only ipsi-CLNM | 82 (52.2) |
| Skip-CLNM | 3 (1.9) |
| Number of CLNM (mean ± SD, range) | |
| Con-CLNM | 2.99 ± 2.54 (1–15) |
| Ipsi-CLNM | 4.12 ± 3.30 (1–20) |
| Ipsi-LLNM | 86 (34.4) |
| With con-CLNM | 48 (55.8) |
Abbreviations: bi-CLNM, bilateral central lymph node metastasis; CLNM, central lymph node metastasis; cN0, clinical N0; cN1, clinical N1; con-CLNM, contralateral central lymph node metastasis; ETE, extrathyroid extension; ipsi-CLNM, ipsilateral central lymph node metastasis; ipsi-LLNM, ipsilateral lateral lymph node metastasis; PTC, papillary thyroid carcinoma; SD, standard deviation; Skip-CLNM, contralateral skip central lymph node metastasis.